The Latest Breaking News from Charles River Laboratories

Despite Charles River Laboratories' weak performance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain moderately optimistic about its prospects.

Charles River Laboratories is scheduled to announce its first-quarter results next week, with analysts anticipating a single-digit earnings dip.

Charles River Laboratories underperformed the Dow recently, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

Charles River Laboratories slashed its outlook for 2024 due to light pharma demand, and CRL stock plummeted in early trades.

Charles River Laboratories is poised to release its second-quarter earnings next month, and analysts expect a double-digit earnings dip.

The S&P 500 index is up slightly in 2024, but many components are big losers, including Dow Jones giant Boeing and Tesla.

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.17%. Stocks on Tuesday settled mixed. Reduced expectations for...

Horseshoe crab blood is used to test vaccines around the world. But while Europe has approved a synthetic alternative, biomedical labs are bleeding more crabs from the Atlantic Coast.

Charles River Laboratories announced a shortfall in monkey shipments on Wednesday that weighed on its 2023 outlook, and CRL stock toppled.